Q3 2016 EPS Estimates for ICU Medical Inc. Boosted by Roth Capital (ICUI)
ICU Medical Inc. (NASDAQ:ICUI) – Equities research analysts at Roth Capital increased their Q3 2016 earnings estimates for ICU Medical in a note issued to investors on Thursday. Roth Capital analyst C. Lewis now anticipates that the firm will post earnings per share of $1.01 for the quarter, up from their previous forecast of $0.93. Roth Capital also issued estimates for ICU Medical’s Q4 2016 earnings at $0.95 EPS, FY2016 earnings at $3.90 EPS, Q3 2017 earnings at $1.08 EPS and FY2017 earnings at $4.21 EPS.
ICU Medical (NASDAQ:ICUI) last posted its earnings results on Monday, August 8th. The company reported $1.15 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.05 by $0.10. The firm had revenue of $96.70 million for the quarter, compared to analyst estimates of $89.66 million. ICU Medical had a return on equity of 10.33% and a net margin of 14.94%. The company’s revenue for the quarter was up 15.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.97 earnings per share.
Several other brokerages also recently issued reports on ICUI. Piper Jaffray Cos. reiterated a “neutral” rating and set a $119.00 price target (up from $115.00) on shares of ICU Medical in a report on Thursday, August 11th. Zacks Investment Research upgraded ICU Medical from a “hold” rating to a “buy” rating and set a $141.00 price objective for the company in a report on Wednesday, September 21st.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/10/q3-2016-eps-estimates-for-icu-medical-inc-boosted-by-roth-capital-icui.html
ICU Medical (NASDAQ:ICUI) opened at 149.65 on Monday. The firm’s 50-day moving average price is $126.14 and its 200 day moving average price is $112.44. The company has a market capitalization of $2.41 billion, a price-to-earnings ratio of 44.57 and a beta of 0.37. ICU Medical has a 12-month low of $85.56 and a 12-month high of $150.37.
Hedge funds have recently modified their holdings of the stock. Victory Capital Management Inc. boosted its stake in shares of ICU Medical by 69.3% in the second quarter. Victory Capital Management Inc. now owns 366,618 shares of the company’s stock worth $41,336,000 after buying an additional 150,066 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of ICU Medical by 67.5% in the second quarter. JPMorgan Chase & Co. now owns 309,998 shares of the company’s stock worth $34,953,000 after buying an additional 124,920 shares during the period. Royal Bank of Canada boosted its stake in shares of ICU Medical by 1,469.8% in the first quarter. Royal Bank of Canada now owns 131,830 shares of the company’s stock worth $13,725,000 after buying an additional 123,432 shares during the period. Champlain Investment Partners LLC boosted its stake in shares of ICU Medical by 19.8% in the second quarter. Champlain Investment Partners LLC now owns 479,060 shares of the company’s stock worth $54,014,000 after buying an additional 79,235 shares during the period. Finally, Silvercrest Asset Management Group LLC boosted its stake in shares of ICU Medical by 14.8% in the first quarter. Silvercrest Asset Management Group LLC now owns 512,923 shares of the company’s stock worth $53,396,000 after buying an additional 65,978 shares during the period. 89.50% of the stock is currently owned by institutional investors and hedge funds.
In other ICU Medical news, VP Steven Riggs sold 44,739 shares of the company’s stock in a transaction on Tuesday, September 13th. The shares were sold at an average price of $121.78, for a total transaction of $5,448,315.42. Following the sale, the vice president now owns 675 shares of the company’s stock, valued at $82,201.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Thomas D. Mccall sold 2,071 shares of the company’s stock in a transaction on Thursday, August 11th. The shares were sold at an average price of $126.07, for a total transaction of $261,090.97. Following the sale, the vice president now directly owns 2,129 shares in the company, valued at approximately $268,403.03. The disclosure for this sale can be found here. 15.90% of the stock is owned by corporate insiders.
About ICU Medical
ICU Medical, Inc is engaged in the development, manufacturing and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, closed system transfer devices (CSTD), needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.
Receive News & Ratings for ICU Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.